19 December 2014 - Pharmaceutical company Lannett Company (NYSE:LCI) reported on Thursday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%.

The company stated that Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5% is the therapeutic equivalent to the reference listed drug, Cosopt Ophthalmic Solution, 2%/0.5%, of Oak Pharmaceuticals.

For the year ended October 2014, the total sales of Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%, at Average Wholesale Price (AWP) were approximately USD123m, according to IMS.